The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1276 participants.

Also called NCT04559945

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,276 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04559945
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, France, Italy, Netherlands, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04559945. Allocation not applicable; no masking; primary purpose treatment. Start 2020-11-13 (actual); primary completion 2022-07-18 (actual). Results posted on 2026-05-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System
Condition
Cardiac Rhythm Disorder
Condition
Bradycardia
Intervention (Device)
Aveir VR Leadless Pacemaker System
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct04559945
Content hash
d15d5b4898d3af257a69246e37e5bce0504a53cc4080df9bc12f1a7f3fd97a5e